Efficacy and prognosis of PD-1 inhibitors, trastuzumab, and first-line chemotherapy for HER-2-positive advanced gastric cancer in real-world study

被引：0

作者：

Liu, B. ^{[1
]}

Tao, Y. ^{[1
]}

Ke, Y. ^{[1
]}

Rao, W. ^{[1
]}

Liu, Q. ^{[1
]}

机构：

[1] Nanjing Univ, Affiliated Drum Tower Hosp, Med Sch, Comprehens Canc Ctr, Nanjing, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.193

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

169P

引用

页码：S1470 / S1470

页数：1

共 50 条

[11] Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer
Gurbuz, Mustafa
Akkus, Erman
Sakin, Abdullah
Urvay, Semiha
Demiray, Atike Gokcen
Sahin, Suleyman
Sakalar, Teoman
Erol, Cihan
Sendur, Mehmet ali Nahit
Sahin, Ahmet Bilgehan
Cubukcu, Erdem
Guven, Deniz Can
Kilickap, Saadettin
Ergun, Yakup
Uncu, Dogan
Turhal, Nazim Serdar
Uskent, Necdet
Yesil Cinkir, Havva
Demir, Atakan
Acar, Ramazan
Karadurmus, Nuri
Turker, Sema
Altinbas, Mustafa
Karaoglan, Mert
Cay Senler, Filiz
TUMORI JOURNAL, 2021, 107 (05): : 416 - 423
[12] First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
Chung, Hyun Cheol
Bang, Yung-Jue
S Fuchs, Charles
Qin, Shu-Kui
Satoh, Taroh
Shitara, Kohei
Tabernero, Josep
van Cutsem, Eric
Alsina, Maria
Cao, Zhu Alexander
Lu, Jia
Bhagia, Pooja
Shih, Chie-Schin
Janjigian, Yelena Y.
FUTURE ONCOLOGY, 2021, 17 (05) : 491 - 501
[13] Real-world clinical study of trastuzumab biosimilar (Zercepac) and pertuzumab (Perjeta) in combination with chemotherapy for neoadjuvant treatment of HER-2-positive breast cancer
Bao, Yu-Fei
Yang, Jin-Zhe
Li, Xiu-Feng
Zhu, Jing-Jun
ASIAN JOURNAL OF SURGERY, 2024, 47 (07) : 3225 - 3228
[14] Predictive biomarkers for the efficacy of PD-1 inhibitors plus chemotherapy for gastric/gastroesophageal junction cancer in first-line setting.
Sun, Yu-Ting
Lu, Shi-Xun
Lai, Ming-Yu
Yang, Xia
Guan, Wen-Long
Yang, Li-Qiong
Li, Yu-Hong
Wang, Feng-Hua
Xu, Rui-Hua
Qiu, Miao-Zhen
CANCER RESEARCH, 2022, 82 (12)
[15] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
Wang, Q.
Ma, C.
Wang, T.
Chen, G.
Wang, H.
Mei, J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1063 - S1063
[16] Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
Shang, X. Q.
Wang, T.
Chen, G.
Ma, C.
Wang, H.
Jia, X.
Mei, J.
ANNALS OF ONCOLOGY, 2022, 33 : S1550 - S1550
[17] Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study
Lingyun Zhang
Jiayu Zhang
Yan Wang
Wei Li
Shan Yu
Qian Li
Yiyi Yu
Tianshu Liu
Yuehong Cui
BMC Gastroenterology, 22
[18] Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study
Zhang, Lingyun
Zhang, Jiayu
Wang, Yan
Li, Wei
Yu, Shan
Li, Qian
Yu, Yiyi
Liu, Tianshu
Cui, Yuehong
BMC GASTROENTEROLOGY, 2022, 22 (01)
[19] First-line (1L) anti-PD-1 plus chemotherapy in HER2-negative advanced gastric cancer: Real-world evidence from a single Korean center
Shim, Joosung Gabriel
Jung, Minkyu
Kim, Hyunwook
Kim, Kyoo Hyun
Kim, Taeho
Kim, Youhyun
Shim, Hyo Sup
Kim, Hyunki
Kim, Hyo Song
Lee, Choong-kun
Rha, Sun Young
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 83 - 83
[20] Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy
Shigenori Kadowaki
Toshiki Masuishi
Tetsuya Eto
Yukiya Narita
Hiroya Taniguchi
Takashi Ura
Masashi Ando
Masahiro Tajika
Yasumasa Niwa
Yasushi Yatabe
Kei Muro
Cancer Chemotherapy and Pharmacology, 2017, 80 : 807 - 813

← 1 2 3 4 5 →